ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
Why now
Thesis: Biotech IPO window shows selective reopening
Catalyst to watch: Pricing and first-day trading of the IPO
Main risk: Clinical-stage biotechs can fail trials
Why it matters
A large upsized biotech IPO signals reopening risk appetite for early-stage RNA drug developers, though clinical-stage names carry binary trial risk.
Related assets & topics
Nasdaq Composite · ^IXICHealthcareiShares Biotech ETF · IBBSPDR Biotech ETF · XBISources
- googlenews · news.google.com · 2026-09-25 06:46 UTC